Related by context. All words. (Click for frequent words.) 64 FOLOTYN 63 Genasense 63 picoplatin 63 EFAPROXYN 63 pralatrexate 63 glufosfamide 62 L MTP PE 62 oral ridaforolimus 61 CoFactor 61 talactoferrin 61 Marqibo 61 vandetanib 60 Junovan 60 metastatic castrate resistant 60 refractory multiple myeloma 60 metastatic castration resistant 60 castration resistant prostate cancer 60 blinatumomab 60 sipuleucel T 60 abiraterone acetate 60 satraplatin 59 custirsen 59 prostate cancer CRPC 59 T DM1 59 Amrubicin 59 docetaxel chemotherapy 59 Neuradiab 59 tesmilifene 59 PXD# 59 Dacogen 59 lintuzumab 59 Provenge 59 Targretin 59 eculizumab 59 eltrombopag 59 VIDAZA 59 tanespimycin 59 ELACYT 58 azacitidine 58 Xinlay 58 ADVEXIN 58 bafetinib 58 Cinryze TM 58 Azedra 58 HspE7 58 Vidaza 58 perifosine 58 ASA# 58 LibiGel 58 ONCONASE 58 HER2 positive metastatic breast 58 valopicitabine 58 vinorelbine 58 MDV# 58 metastatic hormone refractory 58 Jevtana 58 Taxotere ® 58 prostate cancer AIPC 58 Proxinium TM 58 docetaxel 57 ZYBRESTAT 57 obatoclax 57 forodesine 57 Bezielle 57 CANCIDAS 57 FOLFOX4 57 belinostat 57 ozarelix 57 NSCLC 57 Zerenex 57 palifosfamide 57 cutaneous T cell 57 PROVENGE sipuleucel T 57 axitinib 57 PROMACTA 57 ZEVALIN 57 bazedoxifene 57 OPAXIO 57 BiovaxID 57 Vectibix 57 ipilimumab 57 INCB# [001] 57 HuMax CD4 57 voreloxin 57 nimotuzumab 57 relapsed SCLC 57 BLP# Liposome Vaccine 57 EOquin TM 57 CR# vcMMAE 57 panitumumab 57 Gemzar ® 57 metastatic renal cell carcinoma 57 HRPC 57 NEUVENGE 57 IRX 2 57 Clolar 57 Prostate AdenoCarcinoma Treatment 57 L BLP# 57 hormone refractory prostate cancer 57 fidaxomicin 57 GVAX 57 TELCYTA 57 Advexin 57 pirfenidone 57 ponatinib 57 orBec R 57 PREOS 57 BRIM2 57 bone metastases 57 FOLFIRI 57 decitabine 56 phase IIb clinical 56 alvimopan 56 mRCC 56 IRESSA 56 GATTEX 56 RSR# 56 GVAX immunotherapy 56 Tavocept 56 Plenaxis TM 56 Oncophage 56 HGS ETR1 56 docetaxel Taxotere R 56 APF# 56 ofatumumab 56 Prochymal 56 pegloticase 56 Genasense ® 56 TNFerade 56 DAVANAT 56 afatinib 56 Asentar 56 NATRECOR R 56 Ostarine 56 YONDELIS 56 Cotara 56 mifamurtide 56 Omigard 56 registrational 56 MGCD# [001] 56 elotuzumab 56 Pralatrexate 56 eniluracil 56 NeuroStar TMS Therapy 56 autologous cellular immunotherapy 56 trabectedin 56 Restanza 56 OvaRex ® MAb 56 thymalfasin 56 registrational trial 56 ixabepilone 56 Tarceva TM 56 Amigal 56 romiplostim 56 Folotyn 56 clofarabine 56 relapsed ovarian cancer 56 metastatic HRPC 56 ISTODAX 56 cangrelor 56 relapsed multiple myeloma 56 IMPACT IMmunotherapy 56 temsirolimus 56 sapacitabine 56 velaglucerase alfa 56 Hycamtin 56 TORISEL 56 tivozanib 56 LymphoStat B 55 aflibercept 55 plus prednisone 55 plus dexamethasone 55 metastatic prostate cancer 55 recurrent GBM 55 alvespimycin 55 IMGN# 55 rNAPc2 55 castrate resistant prostate cancer 55 Glufosfamide 55 ANCHOR trial 55 sorafenib Nexavar 55 tamibarotene 55 comparator arm 55 Taxotere R 55 elagolix 55 TOCOSOL Paclitaxel 55 FOLFOX 55 YERVOY 55 lorvotuzumab mertansine 55 infusional 5-FU/LV 55 Ceplene 55 FavId 55 FOLFIRINOX 55 lymphoma CTCL 55 pain palliation 55 amrubicin 55 AzaSite Plus 55 Insegia 55 Fludara 55 Urocidin 55 standard chemotherapy regimen 55 recurrent NSCLC 55 Pirfenidone 55 XL# [003] 55 EOquin 55 relapsed refractory multiple myeloma 55 vosaroxin 55 Dacogen injection 55 ZOLINZA 55 telaprevir 55 free survival PFS 55 Civacir 55 metastatic colorectal cancer 55 rivaroxaban 55 TYKERB 55 goserelin 55 bevacizumab Avastin 55 cell lymphoma CTCL 55 zalutumumab 55 CTCL 55 Stimuvax 55 androgen independent 55 ustekinumab 55 Ophena TM 55 Traficet EN 55 Virulizin R 55 MGCD# [002] 55 trastuzumab 55 Fibrillex TM 55 atrasentan 55 XGEVA 55 cilengitide 55 ambrisentan 55 brentuximab vedotin 55 eribulin 55 OncoVEX GM CSF 55 TRISENOX 55 ERBITUX 55 Combidex 55 R sipuleucel T 55 vemurafenib 55 romidepsin 55 Taxotere chemotherapy 54 BEXXAR 54 metastatic RCC 54 pivotal Phase III 54 ACTEMRA TM 54 Satraplatin 54 pomalidomide 54 Tovaxin 54 MAGE A3 ASCI 54 NEBIDO 54 Alpharadin 54 Xanafide 54 Octreolin 54 Cloretazine R VNP#M 54 IV NSCLC 54 bortezomib 54 EndoTAG TM -1 54 Genasense R 54 BCIRG 54 non metastatic osteosarcoma 54 canakinumab 54 Biologics License Application 54 KRN# 54 low dose cytarabine 54 mipomersen 54 XYOTAX 54 HuMax EGFr 54 Phase Ib 54 ONTAK 54 metastatic breast cancer 54 Xcellerated T Cells 54 LibiGel Phase III 54 pexelizumab 54 plus gemcitabine 54 Albuferon 54 randomized Phase IIb 54 Azixa 54 Leukine 54 Tamibarotene 54 Vicinium TM 54 Fampridine SR 54 oral Xeloda 54 Vandetanib 54 brain metastases 54 LEUKINE 54 PSMA ADC 54 PANVAC VF 54 metastatic CRC 54 vernakalant oral 54 ostarine 54 sunitinib malate 54 zoledronic acid 54 AP# [003] 54 Phase IIB 54 FOLOTYN ® 54 advanced NSCLC 54 CIMZIA ™ 54 investigational monoclonal antibody 54 Torisel 54 non squamous NSCLC 54 diabetic neuropathic pain 54 teduglutide 54 Stedivaze 54 AEGR 54 Chemophase 54 prGCD 54 OMAPRO 54 teriflunomide 54 severe hypercholesterolemia 54 interferon alfa 54 SUTENT 54 pazopanib 54 Theratope 54 AQ4N 54 TELINTRA 54 MOZOBIL 54 abiraterone 54 Phase Ib clinical 54 LibiGel ® 54 resistant ovarian cancer 54 pixantrone 54 PLK1 SNALP 54 Xcytrin 54 ruxolitinib 54 Bronchitol 54 chlorambucil 54 Navelbine ® 54 XELOX 54 dacarbazine 54 GRN#L 54 IPLEX 54 JAK inhibitor 54 Cutaneous T 54 phenoxodiol 54 Phase #/#a trial 54 orBec 54 selective androgen receptor modulator 54 dasatinib 54 dose cohorts 54 Ixempra 54 HGS ETR2 54 mCRC patients 54 iloperidone 53 Fibrin Pad 53 BAY #-# 53 Aurexis 53 velafermin belinostat 53 neratinib 53 Voraxaze ™ 53 IMA# 53 Folfox 53 baminercept 53 PROVENGE ® 53 HER2 positive 53 enzastaurin 53 5-FU/LV 53 CIMZIA TM 53 myelodysplastic syndromes MDS 53 Dasatinib 53 ZACTIMA 53 CTAP# Capsules 53 PDX pralatrexate 53 VPRIV 53 celgosivir 53 gastrointestinal stromal tumors 53 Exelbine 53 leucovorin 53 refractory angina 53 TEMODAL 53 CaP 53 TYSABRI 53 Zenvia ™ 53 non squamous 53 tesetaxel 53 Bicifadine 53 Doxil 53 Myocet 53 Phenoptin 53 surrogate endpoint 53 phase IIb trial 53 PEG SN# 53 Onrigin 53 INCB# [002] 53 BENLYSTA 53 tocilizumab 53 vilazodone 53 Celgene Revlimid 53 gemcitabine chemotherapy 53 entinostat 53 ELND# 53 MyVax R 53 tipranavir 53 Phase IIIb clinical 53 Clolar ® 53 heavily pretreated 53 PRX# 53 rhThrombin 53 sunitinib 53 methylnaltrexone 53 Mepact 53 erlotinib 53 MYDICAR ® 53 lapatinib 53 Pixantrone 53 EDEMA3 53 zanolimumab 53 pertuzumab 53 cancer immunotherapies 53 PLX PAD 53 Orathecin 53 myelofibrosis 53 Triolex 53 ATL# [001] 53 hypoparathyroidism 53 imetelstat 53 KALBITOR 53 dirucotide 53 PRADAXA 53 Nplate 53 liver metastases 53 pseudobulbar affect PBA 53 RE LY 53 lesinurad 53 Hepatocellular Carcinoma HCC 53 recurrent ovarian cancer 53 cintredekin besudotox 53 recurrent GBM patients 53 depsipeptide 53 vorinostat 53 denosumab 53 tecarfarin 53 gefitinib 53 Halaven 53 PROSTVAC TM 53 albinterferon alfa 2b 53 TroVax 53 Lenalidomide 53 trastuzumab DM1 T DM1 53 olaparib 53 BLA filing 53 LEP ETU 53 HERmark 53 dacetuzumab 53 CRMD# 53 degarelix 53 Cloretazine 53 posaconazole 53 TREANDA 53 Abraxane 53 chronic angina 53 mCRC 53 TYGACIL 53 UPLYSO 53 Phase 2b trial 53 Phase 2b clinical 53 HER2 positive breast cancer 53 ADVEXIN clinical 53 ToGA 53 Taxotere 53 CINTREDEKIN BESUDOTOX 53 BRIM3 53 #D#C# 53 denufosol 53 Zevalin 53 refractory Hodgkin lymphoma 53 Phase 1b 53 carfilzomib 53 Ozarelix 53 RG# [001] 53 dextromethorphan quinidine 53 Riquent 53 oblimersen 53 randomized Phase 2b 53 limiting toxicity 53 Allovectin 7 R 53 ataluren 53 pegylated interferon alfa 2b 53 investigational immunotherapy 53 XmAb# 53 Anturol 53 mapatumumab 53 Allovectin 7 53 Curaxin CBLC# 53 elacytarabine 53 ThermoDox ® 53 Ceflatonin 52 Aplidin 52 initiate Phase 1b 52 MyVax 52 Phase 2a trial 52 IL# PE#QQR 52 Lucanix R 52 Cladribine Tablets 52 BYDUREON 52 Avastin bevacizumab 52 Romiplostim 52 HuMax CD# 52 randomized Phase 52 Troxatyl 52 Androxal 52 sargramostim 52 BENLYSTA ® 52 Entereg R 52 B CLL 52 AeroLEF TM 52 sorafenib 52 Anturol TM 52 AGGRASTAT ® 52 cetuximab Erbitux ® 52 Zemplar Capsules 52 metastatic GIST 52 Generx 52 ProSavin 52 OvaRex R 52 liprotamase 52 Trastuzumab 52 neoadjuvant therapy 52 rilonacept 52 Tekturna HCT 52 DOXIL 52 Dalbavancin 52 dacarbazine chemotherapy 52 Panzem R NCD 52 prostate cancer mCRPC 52 velafermin 52 ADVENTRX 52 Locteron 52 ILLUMINATE 52 STRIDE PD 52 LEVADEX 52 Xyotax 52 ocrelizumab 52 NUEDEXTA 52 XL# XL# XL# XL# 52 maribavir 52 cabazitaxel 52 Phase IIb clinical 52 PhosLo 52 relapsing multiple sclerosis 52 phase IIa clinical 52 5 Fluorouracil 52 bevacizumab Avastin ® 52 Sym# 52 Cethromycin 52 NEUMUNE 52 docetaxel Taxotere ® 52 ISA# [002] 52 FOLPI 52 SAR# [004] 52 metastatic melanoma 52 SCCHN 52 Phase 2b study 52 ularitide 52 REMINYL ® 52 Doxil ® 52 adjuvant chemotherapy 52 Renal Cell Carcinoma RCC 52 TAXOTERE R 52 idiopathic pulmonary fibrosis IPF 52 pemetrexed 52 ACTEMRA 52 Defibrotide 52 Apoptone 52 KNS # 52 Advaxis Phase 52 PEG Interferon lambda 52 hormone refractory metastatic prostate 52 Vilazodone 52 multiple myeloma MM 52 Elagolix 52 INC# 52 prostate cancer HRPC 52 MAXY G# 52 Navelbine 52 NPSP# 52 darapladib 52 Proellex TM 52 DAVANAT R 52 ferumoxytol 52 FOLFOX6 chemotherapy regimen 52 Genz # 52 Bortezomib 52 iSONEP 52 Telintra 52 KRAS status 52 Tekamlo 52 daclizumab 52 NP2 Enkephalin 52 Topical Interferon Alpha 2b 52 hematologic malignancies 52 apaziquone 52 bosentan 52 Fablyn 52 GSK# [001] 52 refractory gout 52 histone deacetylase HDAC inhibitor 52 stage IIIB 52 Acapodene 52 refractory PTCL 52 leukemia AML 52 metaglidasen 52 refractory chronic lymphocytic 52 lupus nephritis 52 GAMMAGARD 52 PIX# [002] 52 Phase #b/#a clinical 52 Zelrix 52 Arixtra 52 LY# [003] 52 Promacta 52 dose limiting toxicities 52 mocetinostat 52 Telaprevir 52 Pemetrexed 52 monotherapy 52 nab paclitaxel 52 PREOS R 52 refractory AML 52 Pivotal Phase III 52 gastrointestinal stromal tumors GIST 52 tafamidis 52 Zenvia 52 StaphVAX 52 ApoB SNALP 52 dutasteride 52 ThermoDox 52 clodronate 52 adult chronic ITP 52 oral deforolimus 52 IMC A# 52 estramustine 52 Dyloject TM 52 Evoltra TM 52 Fodosine 52 fondaparinux 52 Androxal TM 52 otelixizumab 52 huC# DM4 52 palifermin 52 mitoxantrone 52 deforolimus 52 AVASTIN 52 phase IIb 52 FROVA 52 capecitabine 52 Abiraterone 52 Prestara 51 MoxDuo IR 51 ridaforolimus 51 CYCLOSET 51 APOPTONE 51 temozolomide 51 Raptiva ® 51 Quinamed 51 veltuzumab 51 Azedra TM 51 Velcade bortezomib 51 ONGLYZA 51 Archexin 51 VELCADE 51 ganetespib 51 Virulizin ® 51 Triapine 51 BrachySil TM 51 Specifid 51 Neurodex 51 interferon gamma 1b 51 bevacizumab 51 Canvaxin TM 51 Veronate 51 DXL# 51 CBLC# 51 sBLA 51 TLK# 51 MEND CABG II 51 palliative radiotherapy 51 remission induction 51 mycophenolate mofetil 51 NovoTTF 51 Trofex 51 mertansine 51 IIa trial 51 Fulvestrant 51 Romidepsin 51 Cetuximab 51 TASQ 51 Clofarabine 51 bortezomib Velcade R 51 seliciclib 51 StemEx 51 carboplatin 51 forodesine hydrochloride 51 lapatinib Tykerb 51 dacarbazine DTIC 51 Tarceva 51 Gemcitabine 51 Pennsaid R 51 placebo controlled Phase 51 MGd 51 invasive bladder 51 Removab 51 cutaneous T 51 evaluating tivozanib 51 CBLB# 51 refractory CLL 51 Panitumumab 51 DAPT 51 apremilast 51 Dendreon 51 Phase III 51 anidulafungin 51 metastatic CRPC 51 therapeutic regimens 51 sorafenib tablets 51 erlotinib Tarceva ® 51 ACAPODENE 51 Phase Ib study 51 oxymorphone ER 51 cisplatin vinorelbine 51 Phase 1b clinical 51 evaluable 51 Phase 1b trial 51 bosutinib 51 confirmatory Phase III 51 Denosumab 51 Symadex 51 PREZISTA r 51 samalizumab 51 Gefitinib 51 gefitinib Iressa 51 THALOMID 51 rFIXFc 51 SinuNase 51 cetuximab 51 rituximab 51 systemic ALCL 51 Plicera 51 ARIMIDEX 51 SVR# 51 EVIZON 51 recurrent glioblastoma multiforme 51 Vitaxin 51 gastrointestinal stromal tumor GIST 51 allogeneic stem cell 51 radiation sensitizer 51 Phase Ib II 51 imatinib mesylate Gleevec 51 ARCOXIA 51 DR Cysteamine 51 Tocosol Paclitaxel 51 metastatic androgen independent 51 gemcitabine 51 recurrent glioma 51 pan HDAC inhibitor 51 Zybrestat 51 dose cohort 51 doripenem 51 levosimendan 51 dose escalation 51 prospectively defined 51 orBec ® 51 efalizumab 51 pegfilgrastim 51 Reolysin 51 ARIKACE 51 IVIg 51 Delcath PHP System 51 valsartan 51 OHR/AVR# 51 TAXUS Liberte Stent 51 epratuzumab 51 TYZEKA 51 multiple myeloma 51 nilotinib 51 ALIMTA 51 unresectable Stage III 51 carboplatin paclitaxel 51 davunetide 51 Diabetic Macular Edema 51 Cloretazine ® 51 FOLFOX6 51 Platinol 51 REOLYSIN ® 51 LUCENTIS 51 pradefovir 51 cytotoxic therapy 51 Genasense ® oblimersen 51 platinum refractory 51 XYOTAX TM 51 pegylated interferon alpha 51 anti EGFR antibody 51 Hodgkin lymphoma NHL 51 cetuximab Erbitux 51 ZYVOX 51 Cimzia TM 51 APTIVUS r 51 Erlotinib 51 dabigatran etexilate 51 Evoltra 51 pharmacokinetic PK 51 COPAXONE ® 51 CEQ# 51 personalized immunotherapy 51 sevelamer 51 ARIKACE ™ 51 CRx 51 CCX# B 51 liposomal doxorubicin 51 ACZ# 51 Mylotarg 51 STELARA 51 GATTEX TM 51 lomitapide 51 superficial bladder cancer 51 humanized anti 51 FTY# 51 Elitek 51 clinical trial 51 Gliadel Wafer 51 GRNVAC1 51 systemic anaplastic large 51 novel histone deacetylase 51 AGGRASTAT R 51 lumiliximab 51 luteinizing hormone releasing 51 oral prodrug 51 diagnosed multiple myeloma 51 vernakalant 51 Onconase 51 Celacade 51 GALNS 51 ANTEGREN 51 cancer mCRC 51 MERLIN TIMI 51 Campath 51 adecatumumab 51 AEG# 51 oxaliplatin 51 PEG INTRON 51 DexaSite 51 CYT# 51 odanacatib 51 pediatric acute lymphoblastic 51 hA# 51 mcg dose 51 MabCampath 51 TheraSphere 51 evaluable patients 51 unresectable stage 51 tolevamer 50 Erbitux 50 tramiprosate 50 TRIOLEX 50 Natalizumab 50 toremifene 50 Alkeran 50 farletuzumab 50 Cinryze 50 NOXAFIL 50 trastuzumab emtansine T DM1 50 Zolinza 50 Phase III TRIST 50 Evoltra ® 50 PrevOnco 50 Avastin 50 Zarnestra 50 AVADO 50 DASISION 50 trastuzumab Herceptin 50 rindopepimut 50 Endeavor stent 50 eribulin mesylate 50 QNEXA 50 CALGB # [001] 50 allogeneic 50 Acetavance 50 ZEGERID Capsules 50 REBETOL 50 acute coronary syndromes ACS 50 oxaliplatin Eloxatin 50 Soliris 50 ALKS 50 Revlimid lenalidomide 50 VEGF Trap 50 adjuvant radiation 50 tolerated dose MTD 50 refractory metastatic 50 CD3 monoclonal antibody 50 LEVADEX ™ 50 fluoropyrimidine 50 dexanabinol 50 ALN VSP 50 Nexavar 50 rALLy trial 50 NUVIGIL 50 bremelanotide 50 INTELENCE 50 indiplon capsules 50 mg dose 50 CD# antibody [001] 50 UVIDEM 50 Atiprimod 50 doxorubicin HCl liposome injection 50 VELCADE melphalan 50 omacetaxine mepesuccinate 50 brivaracetam 50 orphan medicinal product 50 bendamustine 50 cethromycin 50 bucindolol 50 #I TM# 50 cetuximab Erbitux R 50 Canvaxin 50 biliary tract cancer 50 concurrent chemoradiation 50 oritavancin 50 Allovectin 7 ® 50 Ambrisentan 50 pivotal Phase 50 recurrent metastatic 50 belimumab 50 Abiraterone acetate 50 Neulasta ® 50 HEPLISAV 50 PRTX 50 LE DT 50 virologic response 50 Exelixis XL# 50 Panzem 50 Xelox 50 Epratuzumab 50 Sandostatin LAR 50 maximally tolerated dose 50 Zytiga 50 ticagrelor 50 Multikine 50 Imprime PGG 50 GvHD 50 INT# [002] 50 anastrozole 50 clinical trials 50 HQK 50 HBeAg positive patients 50 Ventavis 50 metastatic colorectal 50 paclitaxel 50 trastuzumab DM1 50 Vivaglobin 50 anti leukemic 50 linaclotide 50 sorafenib Nexavar ® 50 trastuzumab Herceptin R 50 dalbavancin 50 Cethrin 50 Pixuvri 50 tolvaptan 50 Adalimumab 50 teriparatide 50 RECOTHROM 50 modified glutathione analog 50 Advagraf 50 T#I [002] 50 Viramidine 50 Alemtuzumab 50 paclitaxel Taxol 50 pegylated liposomal doxorubicin 50 patients evaluable 50 fenofibric acid 50 Neoadjuvant 50 torezolid phosphate 50 diagnosed GBM 50 anti CD# antibodies 50 Alocrest 50 Irinotecan 50 lintuzumab SGN 50 EndoTAGTM 1 50 squamous histology 50 FIRMAGON R 50 galiximab 50 BiDil 50 Menerba 50 oral rivaroxaban 50 phase IIa 50 colorectal liver metastases 50 MBP# [001] 50 urocortin 2 50 TRISENOX ® 50 ISEL 50 Phase IIa clinical 50 Genentech Roche 50 Soliris eculizumab 50 PS# [001] 50 BioNumerik 50 antibody MAb 50 chemoradiotherapy 50 acyclovir Lauriad R 50 opioid induced bowel dysfunction